SCHEMBL752822

SCHEMBL752822

CC(=O)Nc1ccc(Nc2nc3ccc(-c4cccc(S(C)(=O)=O)c4)nn3c2-c2cc(N)nc(C)n2)cc1

nearest known ligand 0.45

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
FYN P06241 6/20 0.45
KCNH2 Q12809 4/20 0.44
PIK3CG P48736 2/20 0.42
PIK3CD O00329 1/20 0.42
PIK3CA P42336 3/20 0.41
MTOR P42345 3/20 0.41
POLB P06746 1/20 0.40
GAA P10253 1/20 0.40
KDM4E B2RXH2 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
HTT P42858 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
PRKDC P78527 1/20 0.39
ATM Q13315 1/20 0.39
ATR Q13535 1/20 0.39
PIK3CB P42338 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2791183 0.94 FYN (0.48) FYNKCNH2PIK3CGPIK3CDPIK3CA
SCHEMBL11030991 0.92 KCNH2 (0.46) KCNH2PIK3CAMTORKDM4ESMN1; SMN2
SCHEMBL11026266 0.88 KCNH2 (0.45) FYNKCNH2PIK3CGPIK3CDPIK3CA
SCHEMBL751893 0.82 MTOR (0.47) KCNH2PIK3CAMTORKDM4ESMN1; SMN2
SCHEMBL2789279 0.82 PIK3CA (0.43) KCNH2PIK3CAMTORKDM4ESMN1; SMN2
SCHEMBL754686 0.77 KDM4E (0.44) FYNPIK3CAMTORKDM4ESMN1; SMN2
SCHEMBL2774275 0.74 PIK3CA (0.60) PIK3CGPIK3CDPIK3CAMTORPIK3CB
SCHEMBL753598 0.73 KCNH2 (0.43) KCNH2PIK3CAMTORKDM4ESMN1; SMN2
SCHEMBL750572 0.73 PIK3CA (0.60) PIK3CGPIK3CDPIK3CAMTORKDM4E
SCHEMBL753051 0.70 PIK3CA (0.58) PIK3CGPIK3CDPIK3CAMTORPIK3CB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2430013-B1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS AMGEN INC (US) 2014-10-15 EP claimed
US-20120190666-A1 Heteroaryl Compounds as PIKK Inhibitors AMGEN INC. (US) 2012-07-26 US claimed
EP-2430013-A1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS Amgen, Inc (US) 2012-03-21 EP claimed
EP-2430013-B1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS AMGEN INC (US) 2014-10-15 EP disclosed
US-20120190666-A1 Heteroaryl Compounds as PIKK Inhibitors AMGEN INC. (US) 2012-07-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190666-A1 Heteroaryl Compounds as PIKK Inhibitors PIK3CA, PIKFYVE, PIK3CD FYN 476/4885KCNH2 2938/4885PIK3CG 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.